Emily Krueger

Mrs. Emily Krueger

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
EKEmily Krueger
Emily Krueger
TLTrevor S. Lloyd
Trevor S. Lloyd
Jeffery TessemJeffery Tessem
Jeffery Tessem
Since elevated serum levels of trimethylamine N-oxide (TMAO) were first associated with increased risk of cardiovascular disease (CVD), TMAO research among chronic diseases has grown exponentially. We now know that serum TMAO accumulation begins with dietary choline metabolism across the microbiome-liver-kidney axis, which is typically dysregulated during pathogenesis. While CVD research links TMAO to atherosclerotic mechanisms in vascular tissue, its molecular effects on metabolic tissues are unclear. Here we report the current standing of TMAO research in metabolic disease contexts across relevant tissues including the liver, kidney, brain, adipose, and muscle. Since poor blood glucose management is a hallmark of metabolic diseases, we also explore the variable TMAO effects on insulin resistance and insulin production. Among metabolic tissues, hepatic TMAO research is the most common, whereas its effects on other tissues including the insulin producing pancreatic β-cells are largely unexplored. Studies on diseases including obesity, diabetes, liver diseases, chronic kidney disease, and cognitive diseases reveal that TMAO effects are unique under pathologic conditions compared to healthy controls. We conclude that molecular TMAO effects are highly context-dependent and call for further research to clarify the deleterious and beneficial molecular effects observed in metabolic disease research.

17 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
EKEmily Krueger
Emily Krueger
JBJoseph L. Beales
Joseph L. Beales
KRKacie Russon
Kacie Russon
WEWeston Elison
Weston Elison
JDJordan Davs
Jordan Davs
Jeffery TessemJeffery Tessem
Jeffery Tessem
Serum accumulation of the gut microbial metabolite trimethylamine N-oxide (TMAO) is associated with high caloric intake and type 2 diabetes (T2D). Impaired pancreatic β-cell function is a hallmark of diet-induced T2D, which is linked to hyperglycemia and hyperlipidemia. While TMAO production via the gut microbiome-liver axis is well defined, its molecular effects on metabolic tissues are unclear, since studies in various tissues show deleterious and beneficial TMAO effects. We investigated the molecular effects of TMAO on functional β-cell mass. We hypothesized that TMAO may damage functional β-cell mass by inhibiting β-cell viability, survival, proliferation, or function to promote T2D pathogenesis. We treated INS-1 832/13 β-cells and primary rat islets with physiological TMAO concentrations and compared functional β-cell mass under healthy standard cell culture (SCC) and T2D-like glucolipotoxic (GLT) conditions. GLT significantly impeded β-cell mass and function by inducing oxidative and endoplasmic reticulum (ER) stress. TMAO normalized GLT-mediated damage in β-cells and primary islet function. Acute 40µM TMAO recovered insulin production, insulin granule formation, and insulin secretion by upregulating the IRE1α unfolded protein response to GLT-induced ER and oxidative stress. These novel results demonstrate that TMAO protects β-cell function and suggest that TMAO may play a beneficial molecular role in diet-induced T2D conditions.

1 October 2025 in AJPM Focus
Verified
Journal Article
Open access
MSMarissa M Shams-White
Marissa M Shams-White
EFErika J. Faust
Erika J. Faust
MZMeghan Zimmer
Meghan Zimmer
EKEmily Krueger
Emily Krueger
KRKaren S. Regan
Karen S. Regan
JRJill Reedy
Jill Reedy
Diet, physical activity, and sleep are behaviors occurring at regular intervals over the 24-hour period. To better understand how they interact and impact the etiology and prevention of chronic diseases, studies are needed that collect data on all 3 behaviors. This scoping review of the authors’ portfolio aimed to identify cohort and interventional studies funded by the National Cancer Institute; National Heart, Lung, and Blood Institute; and National Institute of Diabetes and Digestive and Kidney Diseases that collected measures on all 3 behaviors, on 2 behaviors to better understand existing gaps, and on those with data across a 24-hour period (temporal data). Cohorts receiving National Cancer Institute funding; studies identified in the National Heart, Lung, and Blood Institute National Sleep Research Resource and National Institute of Diabetes and Digestive and Kidney Diseases Central Repository; and active National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases intervention grants in Fiscal Years 2021–2022 were reviewed. Data were collected from 2021 to 2022 and analyzed from 2022 to 2023. Twenty-nine cohort and 47 interventional studies collected data on all 3 behaviors, of which 3 cohorts and 20 interventions collected temporal data. Forty-two cohort and 160 interventional studies collected data on 2 behaviors, of which 3 cohorts and 50 interventions collected temporal data; sleep data were most commonly missing. The most common temporal measures were 24-hour dietary recalls and actigraphy. Efforts to promote the collection of temporal data on all 3 behaviors simultaneously can support innovative research questions and analytic approaches focused on their interrelationships across the 24-hour period and health outcomes among various populations. Such efforts can inform tailored interventions and precision health research.

28 June 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
EKEmily Krueger
Emily Krueger
LGLaura E. Griffin
Laura E. Griffin
JBJoseph L. Beales
Joseph L. Beales
TLTrevor S. Lloyd
Trevor S. Lloyd
NBNathan J. Brown
Nathan J. Brown
Jeffery TessemJeffery Tessem
Jeffery Tessem
Dietary flavanols are known for disease preventative properties but are often poorly absorbed. Gut microbiome flavanol metabolites are more bioavailable and may exert protective activities. Using metabolite mixtures extracted from the urine of rats supplemented with flavanols and treated with or without antibiotics, we investigated their effects on INS-1 832/13 β-cell glucose stimulated insulin secretion (GSIS) capacity. We measured insulin secretion under non-stimulatory (low) and stimulatory (high) glucose levels, insulin secretion fold induction, and total insulin content. We conducted treatment-level comparisons, individual-level dose responses, and a responder vs. non-responder predictive analysis of metabolite composition. While the first two analyses did not elucidate treatment effects, metabolites from 9 of the 28 animals demonstrated significant dose responses, regardless of treatment. Differentiation of responders vs. non-responder revealed that levels of native flavanols and valerolactones approached significance for predicting enhanced GSIS, regardless of treatment. Although treatment-level patterns were not discernable, we conclude that the high inter-individual variability shows that metabolite bioactivity on GSIS capacity is less related to flavanol supplementation or antibiotic treatment and may be more associated with the unique microbiome or metabolome of each animal. These findings suggest flavanol metabolite activities are individualized and point to the need for personalized nutrition practices.